DRL’s Resof Total tablets are available in bottle count size of 28
Dr Reddy’s Laboratories (DRL) has launched the generic version of Sofosbuvir 400mg and Velpatasvir 100mg fixed-dose combination, indicated for the treatment of Chronic Hepatitis C, under a brand name Resof Total, in India.
DRL’s Resof Total tablets are available in bottle count size of 28.
Resof Total is used for the treatment of adult patients with Chronic Hepatitis C Virus, Genotype 1,2,3,4,5 or 6 infection
– Without Cirrhosis or with compensated cirrhosis
– With decompensated cirrhosis for use in combination with Ribavirin
The Sofosbuvir 400mg and Velpatasvir 100mg fixed-dose combination is a generic version of Gilead’s brand Epclusa. Treatment with this combination achieves a cure rate of more than 90 per cent in all genotypes of Hepatitis C virus (1,23,4, or 6). Achievement of higher cure rate with this combination in Hepatitis C genotype 3 addresses a significant unmet need, since infection with genotype 3 of Hepatitis C is upto 70 per cent in Indian patients infected with Hepatitis C.